Peer Reviewed
Feature Article Lipid disorders
Lipid disorders: the challenge of patient management
Abstract
Lipid abnormalities play a key role in the development of coronary heart disease (CHD). Lipid-lowering therapy reduces the risk of a future coronary event in those with or without prior CHD and reduces the risk of stroke in those with prior CHD. Statins are the first choice in drug therapy for a predominant cholesterol problem, whereas for a predominant triglyceride problem fibrates are still the first option for treatment.
Key Points
- Blood lipids are important factors in coronary heart disease.
- Lipid therapy safely and effectively reduces coronary risk and increases life expectancy.
- Lipids assume their greatest importance in those patients with prior CHD or in those with multiple risk factors.
- Statins are the first choice in drug selection for a predominant cholesterol problem.
- Fibrates are the first choice in drug selection for a predominant triglyceride problem.
Get full access
Buy this article
Single article purchases are temporarily unavailable due to site maintenance.
If you would like to purchase an article during this time, please email us at [email protected] with the article details and we'll assist you directly. We'll also let you know when online purchasing is available again.
Thank you for your patience and understanding.
Already a subscriber? Login here.